title: Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature.
abstract: OBJECTIVE
  To estimate the cost-effectiveness of growth hormone (GH) therapy for idiopathic short stature (ISS).
  
  
  METHODS
  Cost-effectiveness analysis.
  
  
  METHODS
  Decision model.
  
  
  METHODS
  A cohort of 10-year-old prepubertal boys with ISS treated with GH.
  
  
  METHODS
  Comparison of children treated for 5 years with GH therapy vs children receiving no intervention.
  
  
  METHODS
  Incremental cost per child, incremental growth per child, and incremental cost per inch of final height gain.
  
  
  RESULTS
  The estimated incremental cost-effectiveness ratio of GH therapy for ISS in the base case analysis compared with no therapy was 52,634 dollars per inch (per 2.54 cm), or 99,959 dollars per child, reflecting an incremental growth of 1.9 in (4.8 cm). Alternate treatment strategies such as increased duration of GH treatment and high pubertal dosing of GH did not substantially improve the cost-effectiveness ratio. Probabilistic sensitivity analyses showed that growth variability in response to GH had the greatest impact on the cost-effectiveness of GH therapy.
  
  
  CONCLUSIONS
  Targeted treatment of children with ISS with the greatest potential for growth appears critical for maximizing cost-effectiveness of GH treatment. However, the significance of the cost per inch is difficult to judge until the utility gains associated with height gain after GH therapy for ISS can be ascertained.
authors.affiliation: Division of Pediatric Endocrinology, University of Michigan, Ann Arbor 48109-0456, USA. joyclee@umich.edu
authors.forename: Joyce M
authors.initials: JM
authors.lastname: Lee
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Davis
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Clark
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Hofer
authors.forename: Alex R
authors.initials: AR
authors.lastname: Kemper
mesh_terms: D001827:Body Height; D002648:Child; D015331:Cohort Studies; D016001:Confidence Intervals; D003362:Cost-Benefit Analysis; D006130:Growth Disorders / Q000188:drug therapy* / Q000191:economics*; D013006:Growth Hormone / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012649:Self Concept
chemical_list: D013006:Growth Hormone